FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last) C/O AM	1. Name and Address of Reporting Person* Crowley John F (Last) (First) (Middle) C/O AMICUS THERAPEUTICS, INC. 3675 MARKET STREET					2. Issuer Name and Ticker or Trading Symbol AMICUS THERAPEUTICS, INC. [FOLD] 3. Date of Earliest Transaction (Month/Day/Year) 07/03/2023 4. If Amendment, Date of Original Filed (Month/Day/Year)									Check X X	Office Direct Office below	er (give title	e Cha	10% O Other (below)	wner specify
(Street) PHILADELPHIA PA 19104															Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)							Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Table	I - I	Non-Deriva	tive	Sec	uriti	ies /	Acq	uire	d, Di	isposed o	of, or	Benefic	cially	Owr	ned			
Date				2. Transaction Date (Month/Day/Yea	2A. Deem Execution if any (Month/Da		ion D	on Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a			and 5) Sec Bei Ow Fol		ving	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
										ode	v	Amount	(A) or (D)	Price	Price		Reported Transaction(s) (Instr. 3 and 4)			
Common Stock 07/					3					S		6,044	D	\$12.31	07(1)	944,229		D		
Common Stock																6	4,895		I	By Trust
		Tab	ole	II - Derivativ (e.g., pu								posed of converti				Owne	ed	•		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Ex if a	a. Deemed decution Date, any Ionth/Day/Year)		ansaction of Derivat Securit Acquir (A) or Dispos of (D) (Instr. and 5)		tive ties red sed	Expi (Mor	ration hth/Day	(/Year)	Amo Secu Unde Deriv Secu (Inst	Amount or Number of	t r				10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

Explanation of Responses:

1. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from \$12.26 to \$12.46 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

All transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2022. In addition to the reported transactions, Mr. Crowley also has approximately 738,000 options outstanding and exercisable at various strike prices.

/s/ Christian Formica, Attorney-in-Fact 07/06/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.